Skip to content 
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts. more
| Time Frame | PRTC | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 1.31% | -3.93% | -0.67% |
| 1-Month Return | -6.08% | -2.41% | -1.33% |
| 3-Month Return | 1.43% | 1.64% | -0.29% |
| 6-Month Return | 3.41% | 11.65% | 5.08% |
| 1-Year Return | -6.75% | 3.11% | 19.01% |
| 3-Year Return | -36.44% | 19.21% | 68.62% |
| 5-Year Return | -67.33% | 36.52% | 78.6% |
| 10-Year Return | -55.87% | 126.5% | 240.69% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 8.34M | 9.98M | 2.09M | 3.33M | 4.83M | [{"date":"2020-12-31","value":83.59,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":20.94,"profit":true},{"date":"2023-12-31","value":33.37,"profit":true},{"date":"2024-12-31","value":48.38,"profit":true}] |
| Cost of Revenue | - | 110.47M | 152.43M | 4.93M | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":72.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":3.24,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | 8.34M | (100.49M) | (136.81M) | (1.60M) | 1.26M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1204.8,"profit":false},{"date":"2022-12-31","value":-1640.27,"profit":false},{"date":"2023-12-31","value":-19.22,"profit":false},{"date":"2024-12-31","value":15.07,"profit":true}] |
| Gross Margin | 100.00% | (1007.03%) | (6546.17%) | (48.14%) | 26.04% | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1007.03,"profit":false},{"date":"2022-12-31","value":-6546.17,"profit":false},{"date":"2023-12-31","value":-48.14,"profit":false},{"date":"2024-12-31","value":26.04,"profit":true}] |
| Operating Expenses | 127.87M | 160.26M | 60.99M | 54.55M | 140.41M | [{"date":"2020-12-31","value":79.79,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":38.06,"profit":true},{"date":"2023-12-31","value":34.04,"profit":true},{"date":"2024-12-31","value":87.61,"profit":true}] |
| Operating Income | (119.53M) | (150.28M) | (197.81M) | (146.20M) | (136.09M) | [{"date":"2020-12-31","value":-11953100000,"profit":false},{"date":"2021-12-31","value":-15028200000,"profit":false},{"date":"2022-12-31","value":-19780700000,"profit":false},{"date":"2023-12-31","value":-14619900000,"profit":false},{"date":"2024-12-31","value":-13609500000,"profit":false}] |
| Total Non-Operating Income/Expense | 136.74M | 86.83M | 106.87M | 112.62M | 172.50M | [{"date":"2020-12-31","value":79.27,"profit":true},{"date":"2021-12-31","value":50.34,"profit":true},{"date":"2022-12-31","value":61.95,"profit":true},{"date":"2023-12-31","value":65.29,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Pre-Tax Income | 18.97M | (58.95M) | (92.78M) | (36.10M) | 23.77M | [{"date":"2020-12-31","value":79.79,"profit":true},{"date":"2021-12-31","value":-247.97,"profit":false},{"date":"2022-12-31","value":-390.27,"profit":false},{"date":"2023-12-31","value":-151.86,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income Taxes | 14.40M | 3.76M | (55.72M) | 30.52M | (4.01M) | [{"date":"2020-12-31","value":47.18,"profit":true},{"date":"2021-12-31","value":12.3,"profit":true},{"date":"2022-12-31","value":-182.54,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-13.13,"profit":false}] |
| Income After Taxes | 4.57M | (62.71M) | (37.06M) | (66.63M) | 27.78M | [{"date":"2020-12-31","value":16.44,"profit":true},{"date":"2021-12-31","value":-225.72,"profit":false},{"date":"2022-12-31","value":-133.41,"profit":false},{"date":"2023-12-31","value":-239.82,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income From Continuous Operations | 4.57M | (62.71M) | (37.06M) | (66.63M) | 27.78M | [{"date":"2020-12-31","value":16.44,"profit":true},{"date":"2021-12-31","value":-225.72,"profit":false},{"date":"2022-12-31","value":-133.41,"profit":false},{"date":"2023-12-31","value":-239.82,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | 5.99M | (60.56M) | (50.35M) | (65.70M) | 53.51M | [{"date":"2020-12-31","value":11.18,"profit":true},{"date":"2021-12-31","value":-113.17,"profit":false},{"date":"2022-12-31","value":-94.1,"profit":false},{"date":"2023-12-31","value":-122.78,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| EPS (Diluted) | 1.47 | - | - | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| PRTC | |
|---|---|
| Cash Ratio | 7.92 |
| Current Ratio | 8.49 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| PRTC | |
|---|---|
| ROA (LTM) | -12.95% |
| ROE (LTM) | 9.44% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| PRTC | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.33 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.68 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| PRTC | |
|---|---|
| Trailing PE | 10.11 |
| Forward PE | NM |
| P/S (TTM) | 65.01 |
| P/B | 1.10 |
| Price/FCF | NM |
| EV/R | 16.97 |
| EV/Ebitda | 2.77 |
PureTech Health PLC (PRTC) share price today is $16.8
Yes, Indians can buy shares of PureTech Health PLC (PRTC) on Vested. To buy
Yes, you can purchase fractional shares of PureTech Health PLC (PRTC) via the Vested app. You can start investing in PureTech Health PLC (PRTC) with a minimum investment of $1.
You can invest in shares of PureTech Health PLC (PRTC) via Vested in three simple steps:
The 52-week high price of PureTech Health PLC (PRTC) is $20. The 52-week low price of PureTech Health PLC (PRTC) is $13.3.
The price-to-earnings (P/E) ratio of PureTech Health PLC (PRTC) is 10.1118
The price-to-book (P/B) ratio of PureTech Health PLC (PRTC) is 1.10
The dividend yield of PureTech Health PLC (PRTC) is 0.00%
The market capitalization of PureTech Health PLC (PRTC) is $415.45M
The stock symbol (or ticker) of PureTech Health PLC is PRTC
Consider the share price of PureTech Health PLC as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether PureTech Health PLC has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in PureTech Health PLC shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the PureTech Health PLC stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of PureTech Health PLC and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that PureTech Health PLC stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
